These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 17404489

  • 1. [RANKL as a target molecule for treatment of joint destruction].
    Tanaka S.
    Clin Calcium; 2007 Apr; 17(4):586-92. PubMed ID: 17404489
    [Abstract] [Full Text] [Related]

  • 2. [Molecular mechanisms of bone destruction in rheumatoid arthritis].
    Nanki T.
    Clin Calcium; 2007 Apr; 17(4):510-6. PubMed ID: 17404479
    [Abstract] [Full Text] [Related]

  • 3. [Osteoclast differentiation and activation].
    Takayanagi H.
    Clin Calcium; 2007 Apr; 17(4):484-92. PubMed ID: 17404476
    [Abstract] [Full Text] [Related]

  • 4. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S, Nakamura K, Takahasi N, Suda T.
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [Abstract] [Full Text] [Related]

  • 5. [Pathologic condition of osteoporosis in rheumatoid arthritis].
    Suwa A, Saito E, Wakabayashi T, Suzuki Y.
    Clin Calcium; 2007 Aug; 17(8):1262-6. PubMed ID: 17660625
    [Abstract] [Full Text] [Related]

  • 6. Bone and joint destruction in rheumatoid arthritis: what is really happening?
    Goldring SR.
    J Rheumatol Suppl; 2002 Sep; 65():44-8. PubMed ID: 12236623
    [Abstract] [Full Text] [Related]

  • 7. [Role of osteoclasts in bone destruction in rheumatoid arthritis].
    Suzuki Y.
    Nihon Rinsho Meneki Gakkai Kaishi; 2001 Jun; 24(3):87-97. PubMed ID: 16578961
    [No Abstract] [Full Text] [Related]

  • 8. [RANKL/RANK signaling in rheumatoid arthritis].
    Omata Y, Tanaka S.
    Clin Calcium; 2011 Aug; 21(8):1175-80. PubMed ID: 21814022
    [Abstract] [Full Text] [Related]

  • 9. [Molecular determinants in osteoclast differentiation and osteoimmunology].
    Takayanagi H.
    Rinsho Ketsueki; 2009 Jun; 50(6):447-52. PubMed ID: 19571503
    [No Abstract] [Full Text] [Related]

  • 10. [Expectation for alleviation of joint destruction in rheumatoid arthritis by new molecular targeting pharmaceutics including anti-rankle antibody].
    Nakamura T.
    Clin Calcium; 2009 Mar; 19(3):381-6. PubMed ID: 19252248
    [Abstract] [Full Text] [Related]

  • 11. [Molecular mechanism of bone destruction].
    Inoue H, Takayanagi H.
    Clin Calcium; 2009 Mar; 19(3):339-46. PubMed ID: 19252243
    [Abstract] [Full Text] [Related]

  • 12. [Involvement of osteoclasts in cartilage and bone destruction in rheumatoid arthritis].
    Hikita A, Tanaka S.
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():84-6. PubMed ID: 15799323
    [No Abstract] [Full Text] [Related]

  • 13. [Prevention of joint destruction by osteoclast-targeting therapy in search of new tools, such as OPG or cathepsin K inhibitor].
    Kadono Y, Tanaka S.
    Clin Calcium; 2009 Mar; 19(3):387-93. PubMed ID: 19252249
    [Abstract] [Full Text] [Related]

  • 14. [Bone disease related to rheumatoid arthritis].
    Tanaka S.
    Nihon Rinsho; 2006 Sep; 64(9):1712-7. PubMed ID: 16972685
    [Abstract] [Full Text] [Related]

  • 15. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S.
    Am J Nephrol; 2007 Sep; 27(5):466-78. PubMed ID: 17652963
    [Abstract] [Full Text] [Related]

  • 16. [Histopathological features of joint destruction in rheumatoid arthritis (RA)].
    Uzuki M, Sawai T, Sasaki Y.
    Clin Calcium; 2007 Apr; 17(4):474-83. PubMed ID: 17404475
    [Abstract] [Full Text] [Related]

  • 17. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D.
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [Abstract] [Full Text] [Related]

  • 18. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
    Romas E.
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1065-79. PubMed ID: 16301197
    [Abstract] [Full Text] [Related]

  • 19. Erosive arthritis.
    Schett G.
    Arthritis Res Ther; 2007 Dec; 9 Suppl 1(Suppl 1):S2. PubMed ID: 17634141
    [Abstract] [Full Text] [Related]

  • 20. [Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis--new therapeutical opportunities].
    Kmieć Z, Sokołowska I.
    Pol Merkur Lekarski; 2007 Apr; 22(130):300-4. PubMed ID: 17684931
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.